sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Oncology/Cancer Drugs Market by Therapeutic Modalities (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal), Cancer Types (Blood, Breast, Gastrointestinal , Prostate, Skin, Respiratory/Lung Cancer) - Global Opportunity Analysis and Industry Forecast, 2013 - 2020

Oncology/Cancer Drugs Market by Therapeutic Modalities (Chemotherapy, Targeted Therapy, Immunotherapy,...

Home / Categories / Healthcare
Oncology/Cancer Drugs Market by Therapeutic Modalities (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal), Cancer Types (Blood, Breast, Gastrointestinal , Prostate, Skin, Respiratory/Lung Cancer) - Global Opportunity Analysis and Industry Forecast, 2013 - 2020
Oncology/Cancer Drugs Market by Therapeutic...
Report Code
RO1/113/1002

Publish Date
01/Feb/2015

Pages
159
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
CHAPTER 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Market beyond what to expect by 2025

2.1.1 Moderate growth scenario
2.1.2 Rapid growth scenario
2.1.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Development of novel immuno-oncology drug products
3.3 Key findings

3.3.1 Top Factors impacting oncology drugs market
3.3.2 Top investment pockets of oncology drugs market
3.3.3 Top winning strategies of oncology drugs market

3.4 Porter's five forces analysis

3.4.1 Bargaining power of buyers (low)
3.4.2 Bargaining power of suppliers (moderate)
3.4.3 Threat of new entrants (Low)
3.4.4 Threat of substitutes (moderate)
3.4.5 Intense competitive rivalry

3.5 Value chain analysis

3.5.1 Primary activities
3.5.2 Support activities

3.6 Government regulations and reimbursement

3.6.1 Regulations in United States
3.6.2 Regulations in Europe
3.6.3 Regulations in Asia-Pacific
3.6.4 Reimbursement scenario

3.7 Patent analysis

3.7.1 Patent Analysis by type of patents
3.7.2 Patent analysis by geography

3.8 Market share analysis, 2013
3.9 Clinical trials for oncology drugs
3.10 Market dynamics

3.10.1 Drivers

3.10.1.1 Rising incidence and prevalence of various cancer types
3.10.1.2 Growing importance of biological and targeted drug therapies
3.10.1.3 Expiration of key patents and biosimilars impact
3.10.1.4 Acquisitions and collaborations - bolt-on strategies driving the market growth

3.10.2 Restraints

3.10.2.1 High cost of drug development and threat of failure
3.10.2.2 Adverse effects of anti-cancer drug therapy

3.10.3 Opportunities

3.10.3.1 Advancement of anti-cancer drugs research
3.10.3.2 Personalized medicine approach

CHAPTER 4 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES

4.1 Chemotherapy

4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast

4.2 Targeted therapy

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 Immunotherapy (biologics therapy)

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.4 Hormonal therapy

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast

4.5 Others

4.5.1 Market size and forecast

CHAPTER 5 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY CANCER TYPES

5.1 Blood cancer

5.1.1 Epidemiology - prevalence and incidence
5.1.2 Trends in blood cancer treatment
5.1.3 Market size and forecast

5.2 Breast cancer

5.2.1 Epidemiology - prevalence and incidence
5.2.2 Trends in breast cancer treatment
5.2.3 Market size and forecast

5.3 Gastrointestinal cancer

5.3.1 Epidemiology - prevalence and incidence
5.3.2 Trends in treatment of gastrointestinal cancer
5.3.3 Market size and forecast

5.4 Prostate cancer

5.4.1 Epidemiology - prevalence and incidence
5.4.2 Trends in treatment of prostate cancer
5.4.3 Market size and forecast

5.5 Respiratory/lung cancer

5.5.1 Epidemiology - prevalence and incidence
5.5.2 Trends in treatment of lung Cancer
5.5.3 Market size and forecast

5.6 Skin cancer

5.6.1 Epidemiology - prevalence and incidence
5.6.2 Trends in treatment of skin cancer
5.6.3 Market size and forecast

5.7 Other cancers

5.7.1 Trends in treatment of other cancer types

CHAPTER 6 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY

6.1 North America

6.1.1 Market size and forecast
6.1.2 United States

6.1.2.1 Key market trends
6.1.2.2 Market size and forecast

6.1.3 Canada

6.1.3.1 Key market trends
6.1.3.2 Market size and forecast

6.1.4 Mexico

6.1.4.1 Market size and forecast

6.2 Europe

6.2.1 Key market trends
6.2.2 Market size and forecast
6.2.3 Germany

6.2.3.1 Key market trends
6.2.3.2 Market size and forecast

6.2.4 France

6.2.4.1 Key market trends
6.2.4.2 Market size and forecast

6.2.5 United Kingdom

6.2.5.1 Key market trends
6.2.5.2 Market size and forecast

6.2.6 Others

6.2.6.1 Key market trends
6.2.6.2 Market size and forecast

6.3 Asia Pacific

6.3.1 Key market trends

6.3.1.1 Market size and forecast

6.3.2 India

6.3.2.1 Key market trends
6.3.2.2 Market size and forecast

6.3.3 China

6.3.3.1 Key market trends
6.3.3.2 Market size and forecast

6.3.4 Japan

6.3.4.1 Key market trends
6.3.4.2 Market size and forecast

6.3.5 Australia

6.3.5.1 Key market trends
6.3.5.2 Market size and forecast

6.3.6 Others

6.4 LAMEA

6.4.1 GCC (gulf corporation council)

6.4.1.1 Key Market Trends
6.4.1.2 Market size and forecast

6.4.2 Others

6.4.2.1 Market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1 Amgen Inc.

7.1.1 Company overview
7.1.2 Amgen Inc. snapshot
7.1.3 Financial performance
7.1.4 Operating business segment overview
7.1.5 Key strategies and development
7.1.6 SWOT analysis

7.2 Johnson and Johnson

7.2.1 Company overview
7.2.2 Johnson & Johnson snapshot
7.2.3 Operating business segment overview
7.2.4 Financial performance
7.2.5 Key strategies moves and development
7.2.6 SWOT Analysis

7.3 Roche Diagnostics

7.3.1 Company overview
7.3.2 Roche Diagnostics snapshot
7.3.3 Operating business segment overview
7.3.4 Financial performance
7.3.5 Key strategies moves and development
7.3.6 SWOT analysis

7.4 GlaxoSmithKline PLC

7.4.1 Company overview
7.4.2 GlaxoSmithKline PLC Snapshot
7.4.3 Operating business segment overview
7.4.4 Financial performance
7.4.5 Key strategies move and development
7.4.6 SWOT Analysis of GlaxoSmithKline PLC

7.5 Merck & Company

7.5.1 Company overview
7.5.2 Merck & Company snapshot
7.5.3 Operating business segment overview
7.5.4 Financial performance
7.5.5 Key strategies move and development
7.5.6 SWOT analysis

7.6 Novartis AG

7.6.1 Company overview
7.6.2 Novartis AG snapshot
7.6.3 Operating business segment overview
7.6.4 Financial performance
7.6.5 Key strategies move and development
7.6.6 SWOT analysis

7.7 Pfizer

7.7.1 Company overview
7.7.2 Pfizer snapshot
7.7.3 Operating business segment overview
7.7.4 Financial performance
7.7.5 Key strategies move and development
7.7.6 SWOT analysis

7.8 Sanofi

7.8.1 Company overview
7.8.2 Sanofi snapshots
7.8.3 Operating business segment overview
7.8.4 Financial performance
7.8.5 Key strategies move and development
7.8.6 SWOT analysis

7.9 Eli Lilly and Company

7.9.1 Company overview
7.9.2 Eli Lilly and company snapshots
7.9.3 Operating business segment overview
7.9.4 Financial performance
7.9.5 Key strategies move and development
7.9.6 SWOT analysis

7.10 Celgene Corporation

7.10.1 Company overview
7.10.2 Celgene corporation snapshots
7.10.3 Operating business segment overview
7.10.4 Financial performance
7.10.5 Key strategies move and development
7.10.6 SWOT analysis

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com